Skip to content
Original
mp.weixin.qq.com·· 14 hours agoScore75

DualityBio and BioNTech Say Trastuzumab Pamirtecan DYNASTY-Breast02 Trial Hits Primary Endpoint in HR+/HER2-low Metastatic Breast Cancer

In brief

DualityBio and BioNTech announced that DYNASTY-Breast02 (NCT06018337), a global trial of trastuzumab pamirtecan (BNT323/DB-1303) in HR+/HER2-low metastatic breast cancer, met its primary endpoint.

Source: mp.weixin.qq.com · mp.weixin.qq.com

#Clinical readout#Oncology#ADCs & conjugates
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.